SCHEMBL46615

SCHEMBL46615

O=C(O)CCOCCOCCOCCOCCOCCOCCOCCOCCSCc1cccc(C(=O)Nc2ccc(Cl)cc2C(=O)N/N=C/c2ccc(Cl)c(C(F)(F)F)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 13/20 0.54
SLC34A1 Q06495 1/20 0.54
SLC34A3 Q8N130 1/20 0.54
SLC20A1 Q8WUM9 1/20 0.54
HSPH1 Q92598 1/20 0.42
ADCYAP1R1 P41586 4/20 0.37
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36
NR1H4 Q96RI1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15421200 1.00 SLC34A2 (0.54) SLC34A2SLC34A1SLC34A3SLC20A1HSPH1
SCHEMBL46938 0.89 SLC34A2 (0.44) SLC34A2SLC34A1SLC34A3SLC20A1ADCYAP1R1
SCHEMBL15421039 0.89 SLC34A2 (0.44) SLC34A2SLC34A1SLC34A3SLC20A1ADCYAP1R1
SCHEMBL268180 0.86 SLC34A2 (0.57) SLC34A2SLC34A1SLC34A3SLC20A1HSPH1
SCHEMBL268179 0.86 SLC34A2 (0.57) SLC34A2SLC34A1SLC34A3SLC20A1HSPH1
SCHEMBL273926 0.86 SLC34A2 (0.57) SLC34A2SLC34A1SLC34A3SLC20A1HSPH1
SCHEMBL268892 0.85 SLC34A2 (0.56) SLC34A2SLC34A1SLC34A3SLC20A1HSPH1
SCHEMBL274282 0.85 SLC34A2 (0.56) SLC34A2SLC34A1SLC34A3SLC20A1HSPH1
SCHEMBL268893 0.85 SLC34A2 (0.56) SLC34A2SLC34A1SLC34A3SLC20A1HSPH1
SCHEMBL268320 0.83 SLC34A2 (0.78) SLC34A2SLC34A1SLC34A3SLC20A1HSPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2591354-B1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX INC (US) 2016-09-07 EP disclosed
EP-2591354-B1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX INC (US) 2016-09-07 EP disclosed
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2014-01-23 US disclosed
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2014-01-23 US disclosed
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2014-01-23 US disclosed
EP-2591354-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT Ardelyx, Inc. (US) 2013-05-15 EP disclosed
WO-2012006475-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2012-01-12 WO disclosed
WO-2012006475-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC10A2, SLC34A2, SLC34A3 SLC34A2 2/4885SLC34A1 4/4885SLC34A3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.